Nama's AI scorecard currently rates Damora Therapeutics Sell (2.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does DMRA report earnings?

Damora Therapeutics's next scheduled report is on Mar 18, 2027. Analysts expect EPS of -$0.47.

What is the DMRA price target?

The median analyst price target from 9 analysts is $45.00, with a range of $40.00 – $60.00.

Is DMRA Shariah compliant?

Nama's AAOIFI-style screen reads Damora Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Damora Therapeutics (DMRA)

Healthcare · Biotechnology · NASDAQ

Damora Therapeutics (DMRA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.47B and a free-cash-flow yield of -0.6%. Nama's AI scorecard rates it Sell, 2.2 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 2.2/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Rising · +247.8% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-74.4%

How far the last close sits under the highest price of the past five years.

Market cap	$1.47B
Trailing P/E	—
Price / book	2.8
Price / sales	—
FCF yield	-0.6%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

DMRA earnings

Next report: Mar 18, 2027 (Q4 2026, EPS estimate -$0.47). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$0.52	-$0.40	-30.0%	$0
Q2 2026	Aug 10, 2026	-$0.39	-$0.37	-5.4%	$0
Q4 2024	Mar 19, 2025	-$5.00	-$2.82	-77.3%	—
Q3 2024	Nov 1, 2024	-$3.39	-$3.70	+8.4%	—

DMRA analyst price target

Median target $45.00 from 9 analysts, ranging $40.00 – $60.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live DMRA data on Nama Insights →

DMRA FAQ

Is DMRA a buy?: Nama's AI scorecard currently rates Damora Therapeutics Sell (2.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does DMRA report earnings?: Damora Therapeutics's next scheduled report is on Mar 18, 2027. Analysts expect EPS of -$0.47.
What is the DMRA price target?: The median analyst price target from 9 analysts is $45.00, with a range of $40.00 – $60.00.
Is DMRA Shariah compliant?: Nama's AAOIFI-style screen reads Damora Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.